B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Peptide ligand-binding receptors

REACTOME PATHWAY
Reactome: R-HSA-37527665 genes239 compounds

The Peptide ligand-binding receptors pathway (Reactome ID: R-HSA-375276) involves 65 genes and is affected by 239 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

AGTR1AGTR2APLNRAPPAVPR1AAVPR1BAVPR2BDKRB1BDKRB2C5CCKBRCCL2CCR4CCR6CX3CR1CXCL8CXCR1CXCR6ECE1EDNRAEDNRBF2RL1FPR1FPR2FPR3GALR2GALR3GHSRGPER1GRPR+35 more

Compounds Affecting Peptide ligand-binding receptors

#CompoundTargets HitStudies
1Fluspirilene74
2Calcimycin216
3Astemizole Antihistamine drug now withdrawn from280
4Somatostatin300
5Carvedilol296
6Digoxin299
7Clotrimazole296
8Apigenin 5,7,4'-trihydroxy-flavone,300
9Methylene Blue200
10Disulfiram297
11Peptide YY300
122-Chloroadenosine 2-Chloroadenosine.300
13Chlorhexidine299
14Hexachlorophene300
15Thioridazine35
16Somatostatin-28299
17Camptothecin300
18Fentanyl300
19Quercetin300
20candesartan cilexetil [Supplementary Concept]300
21Niclosamide299
22Substance P299
23Aripiprazole298
24Arginine Vasopressin298
25Oxytocin299
26Deamino Arginine Vasopressin46
27Ornipressin82
28Perphenazine297
29Octreotide300
30Morphine294
31Naloxone299
32Nalbuphine298
33Butorphanol299
34Oxycodone298
35Levorphanol297
36Nalorphine300
37Pentazocine299
38Diprenorphine295
39Sufentanil298
40Levallorphan289
41Meperidine297
42Codeine295
43Etorphine300
44cbd298
45cannabidiol296
46Dihydromorphine300
47Alfentanil298
48Hydromorphone297
49Cyclazocine300
50Kaempferols300

About the Peptide ligand-binding receptors Pathway

The Peptide ligand-binding receptors pathway is catalogued in Reactome (ID: R-HSA-375276) and involves 65 genes. In the BiohacksAI corpus, 239 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include AGTR1, AGTR2, APLNR, APP, AVPR1A.